Pourhoseingholi, 2,468 patient N-acetylcysteine late treatment study: 11% lower mortality [p=0.43] https://c19p.org/pourhoseingholina
copied to clipboard
Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study
et al., Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint)
Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing no significant difference with NAC treatment. IR.MUQ.REC.1399.013.
|
risk of death, 11.0% lower, HR 0.89, p = 0.43, treatment 65 of 309 (21.0%), control 274 of 2,159 (12.7%), adjusted per study, multivariable, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pourhoseingholi et al., 26 May 2021, prospective, Iran, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.
Late treatment
is less effective
is less effective
pourhoseingholi
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.